Cardiovascular

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

By

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Sunovion hires former BI exec as VP of marketing

Sunovion hires former BI exec as VP of marketing

By

Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.

How five therapies changed the course of pharma history

How five therapies changed the course of pharma history

By

And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.

Q&A: Cardiogram's Ballinger on using the Apple Watch to track heart rate

Q&A: Cardiogram's Ballinger on using the Apple Watch to track heart rate

By

The app's co-founder discusses how it's educating patients and physicians about artificial intelligence and why Cardiogram is different from other heart-rate tracking apps.

Five things for pharma marketers to know: Friday, September 9, 2016

Five things for pharma marketers to know: Friday, September 9, 2016

By

New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit

Five things for pharma marketers to know: Tuesday, August 30, 2016

Five things for pharma marketers to know: Tuesday, August 30, 2016

By

Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler

Practice Fusion founder launches heart-monitoring wearable

Practice Fusion founder launches heart-monitoring wearable

By

The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

By

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Five things for pharma marketers to know: Thursday, May 12, 2016

Five things for pharma marketers to know: Thursday, May 12, 2016

By

Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart

Five things for pharma marketers to know: Thursday, March 17, 2016

Five things for pharma marketers to know: Thursday, March 17, 2016

By

Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

By

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

Five things for pharma marketers to know: Tuesday, December 15, 2015

Five things for pharma marketers to know: Tuesday, December 15, 2015

By

Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck's Vytorin claims; Pacira settles off-label marketing case with the FDA

Five things for pharma marketers to know: Friday, December 11, 2015

Five things for pharma marketers to know: Friday, December 11, 2015

By

UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto

Five things for pharma marketers to know: Wednesday, December 2, 2015

Five things for pharma marketers to know: Wednesday, December 2, 2015

By

Negative news coverage of statins may lead people to stop taking their medication; second patient dies in Zafgen obesity drug trial; Gilead defends pricing

Five things for pharma marketers to know: Tuesday, November 10, 2015

Five things for pharma marketers to know: Tuesday, November 10, 2015

By

Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug

Five things for pharma marketers to know: Monday, November 9, 2015

Five things for pharma marketers to know: Monday, November 9, 2015

By

More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Five things for pharma marketers to know: Friday, October 23, 2015

Five things for pharma marketers to know: Friday, October 23, 2015

By

Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug

Five things for pharma marketers to know: Tuesday, October 13, 2015

Five things for pharma marketers to know: Tuesday, October 13, 2015

By

Lilly stops trial for experimental heart drug; Turing misses deadline to respond to lawmakers about price increase of Daraprim; the FDA expands indication for Opdivo

Express Scripts to cover Repatha and Praluent

Express Scripts to cover Repatha and Praluent

By

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.

Five things for pharma marketers to know: Friday, September 18, 2015

Five things for pharma marketers to know: Friday, September 18, 2015

By

Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic

Five things for pharma marketers to know: Friday, September 4, 2015

Five things for pharma marketers to know: Friday, September 4, 2015

By

Longer-term use of AstraZeneca's Brilinta approved; Google streamlines health-related searches; Zarxio's price is higher than expected

Five things for pharma marketers to know: Tuesday, September 1, 2015

Five things for pharma marketers to know: Tuesday, September 1, 2015

By

Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

By

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Five things for pharma marketers to know: Monday, August 24

Five things for pharma marketers to know: Monday, August 24

By

AstraZeneca inks cancer development deal; beta-blockers may increase survival in ovarian-cancer patients; OPDP finds corrective ads are ineffective

New data sets up Jardiance  to displace DPP-4 inhibitors

New data sets up Jardiance to displace DPP-4 inhibitors

By

Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.

PCSK9 inhibitors necessitate an update to heart guidelines, CVS Health says

The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines

Five things for pharma marketers to know: Monday, August 10

Five things for pharma marketers to know: Monday, August 10

By

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration

OPINION

Email Newsletters